The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product. This weight loss was better than the amount achieved by Eli Lilly's Zepbound and Novo Nordisk's Wegovy in clinical trials. With VK2735 advancing into late-stage testing, investors know that Viking will be closer to potentially launching what could be a blockbuster drug. Risk-averse investors should probably stay on the sidelines with Viking. However, I think the biotech stock is a great pick for ag ...

It brings the San Diego-based company one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. Shares of both Novo Nordisk and Eli Lilly fell around 2% in premarket trading Thursday. But after receiving written feedback from the Food and Drug Administration, the company has decided to move the injection directly into a phase three trial, CEO Brian Lian said during an earnings call on Wednesday. That decision will like ...

The results from the Phase 2 trial showed much promise with it meeting its primary and all secondary endpoints. That includes significant weight loss for those taking VK2735 when compared to patients taking a placebo. To go along with this, the company reported adjusted EPS of -20 cents in the second quarter of 2024. That's worth highlighting as it beats out Wall Street's estimate of -24 cents for the quarter. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical t ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2024 Earnings Conference Call July 24, 2024 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Asim Rana - Truist Securities Steve Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Roger Song - Jefferies Andrew Hsieh - William Blair Rohit Bhasin - Morgan Stanley Justin Zelin - BTIG Thomas Smith - Leerink Partners Yale Jen - Laidlaw Company Operator Welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...

Exhibit 99.1 Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, July 24, 2024 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2024, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended June 30, 2024, and Other Rec ...

VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 "The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., chief executive officer of Viking. "The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an ap ...

wragg For this particular article, we will be looking at Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) and sharing our findings about the stock, continuing the theme surrounding obesity therapies. VKTX For now, VK2735 has already reported excellent results from its phase 2 clinical trials, with 14.7% of weight loss from base line by Week 13 (subcutaneous injection) and 5.3% by Day 28 (oral). These numbers are very promising indeed, since it delivers excellent weight losses compared to NVO's Wegovy at -7% a ...

Viking's loss estimates have increased from $1.08 per share to $1.11 for 2024 and from $1.42 to $1.45 for 2025 in the past 60 days. Zacks Investment Research Surprise - Reported Earnings History 0 Earnings Whispers Without an approved/marketed product in its portfolio, the focus is expected to be on updates related to Viking's pipeline consisting of three candidates — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH]) and VK0214 (for X-linked adrenoleukodystrophy (X-ALD)]. Viking Therap ...

This biotech stock fits the profile of a potentially big winner to a T. Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candidates with significant commercial potential. Viking Therapeutics (VKTX 0.52%) fits the profile of such a stock to a T. Could Viking be a millionairemaker? What's in Viking T ...